Results Patients From June 2004 through October 2009, a complete of 304 sufferers were signed up for the study. On December 10 The database was shut for final analysis, 2010. Demographic characteristics of the sufferers and baseline clinical features that are believed to end up being clinically relevant21 were well balanced between the two study groups .). Altogether, 605 cycles of EDP and 631 cycles of streptozocin received as first-line therapy .The number of de novo mutations in the SYNGAP1 coding sequence in the individuals with nonsyndromic mental retardation was considerably greater than that in the rest of the tested series consisting of sufferers with autism spectrum disorders or schizophrenia and control topics . As well as the common I1115T variant, three unique heterozygous missense variants had been found in subjects with autism spectrum disorders and schizophrenia . These variants aren’t present in any SYNGAP1 practical domains, are unlikely to end up being pathogenic because these were transmitted from an unaffected parent, and so are predicted to have no effect on protein function .